2025

19. E. De Vita*, Advances in selective targeting of serine hydrolases: A targeted covalent approach against hCES2A mitigates irinotecan toxicity in vivo, Acta Pharm. Sin. B. 2025, 15, 5491–5492.

18. E. De Vita*, R. Page, The phosphate of life, Nat. Chem. 2025, 17, 460.

2024

17. A. A. Antolin, Y. Aye, L. Bar-Peled, E. De Vita, N. Dudkina, M. C Jewett, H. Kiely-Collins, R. Mazitschek, Z. J. Zhang, What is Chemical Biology?, Cell Chem. Biol., 2024, 31, 1562–1565.

16. R. R. Shah, E. De Vita, P. S. Sathyamurthi, D. Conole, X. Zhang, E. Fellows, E. R. Dickinson, C. M. Fleites, M. A. Queisser, J. D. Harling, E. W. Tate, Structure-guided design and optimization of covalent VHL-targeted sulfonyl fluoride PROTACs, J. Med. Chem., 2024, 67, 4641–4654.

2022

15. L. Zhang, S. Lovell, E. De Vita, P. K. A. Jagtap, D. Lucy, A. Goya Grocin, S. Kjaer, A. Borg, J. Hennig, A. K. Miller, E. W. Tate, A KLK6 activity-based probe reveals a role for KLK6 activity in pancreatic cancer cell invasion, J. Am. Chem. Soc., 2022,144, 22493–22504. Featured on Supplementary CoverArt. 

14. Q. Zhang, C. S. Kounde, M. Mondal, J. L. Greenfield, J. R. Baker, S. Kotelnikov, M. Ignatov, C. P. Tinworth, L. Zhang, D. Conole, E. De Vita, D. Kozakov, A. McCluskey, J. D. Harling, M. J. Fuchter. E. W. Tate, Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs), ChemComm, 2022, 58, 10933-10936. 

13. M. Jamshidiha, T. Lanyon-Hogg, C. L. Sutherell, G. B. Craven, M. Tersa, E. De Vita, D. Brustur, I. Pérez-Dorado, S. Hassan, R. Petracca, R. M. Morgan, M. Sanz-Hernández, J. C. Norman, A. Armstrong, D. J. Mann, E. Cota, E. W. Tate, Identification of the first structurally validated covalent ligands of the small GTPase RAB27A, RSC Med Chem, 2022, 13, 150–155.  

12. H. Yoon, E. M. Triplet, W. L. Simon, C-I. Choi, L. S. Kleppe, E. De Vita, A. K. Miller, I. A. Scarisbrick, Blocking Kallikrein 6 promotes developmental myelination, Glia, 2022, 70, 430–450. 

2021

11. S. Santamaria, F. Buemi, E. Nuti, D. Cuffaro, E. De Vita, T. Tuccinardi, A. Rossello, S. Howell, S. Mehmood, A. P. Snijders, and R. de Groot, Development of a fluorogenic ADAMTS-7 substrate, J. Enzyme Inhib. Med. Chem., 2021, 36, 2160–2169. 

10. E. De Vita, D. Lucy, E. W. Tate, Beyond targeted protein degradation: LD·ATTECs clear cellular lipid droplets, Cell Res., 2021, 31, 945–946. 

9. S. Lovell, L. Zhang, T. Kryza, A. Neodo, N. Bock, E. De Vita, E. D. Williams, E. Engelsberger, C. Xu, A. T. Bakker, M. Maneiro, R. J. Tanaka, C. L. Bevan, J. A. Clements, and E. W. Tate, A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer, J. Am. Chem. Soc., 2021, 143, 8911–8924. 

8. M. Maneiro, E. De Vita, D. Conole, C. S. Kounde, Q. Zhang, E. W. Tate, PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs, Prog. Med. Chem., 2021, 60, 67–190. 

2020

7. E. De Vita*, 10 years into the resurgence of covalent drugs, Fut. Med. Chem., 2020, 13, 193–210. 

6. E. De Vita, M. Maneiro, E. W. Tate, The Missing Link between (Un)druggable and Degradable KRAS, ACS Cent. Sci., 2020, 6, 1281–1284. 

5. E. De Vita, N. Smits, H. van den Hurk, E. M. Beck, J. Hewitt, G. Baillie, E. Russell, A. Pannifer, V. Hamon, A. Morrison, S. P. McElroy, P. Jones, N. A. Ignatenko, N. Gunkel, A. K. Miller, Synthesis and Structure‐Activity Relationships of N‐(4‐Benzamidino)‐Oxazolidinones: Potent and Selective Inhibitors of Kallikrein‐Related Peptidase 6, ChemMedChem, 2020, 15, 79–95. 

2019

4. F. D’Andrea, E. Nuti, S. Becherini, D. Cuffaro, E. Husanu, C. Camodeca, E. De Vita, M. R. Zocchi, A. Poggi, C. D’Arrigo, V. Cappello, M. Gemmi, S. Nencetti, C. Chiappe, A. Rossello, Design and synthesis of ionic liquid-based Matrix Metalloproteinase Inhibitors (MMPIs): a simple approach to increase hydrophilicity and to develop MMPI-coated gold nanoparticles, ChemMedChem, 2019, 14, 686–698. 

2018

3. R. Longuespée, A. K. Wefers, E. De Vita, A. K. Miller, D. E. Reuss, W. Wick, C. Herold-Mende, M. Kriegsmann, P. Schirmacher, A. von Deimling, S. Pusch, Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry, Acta Neuropathol. Commun., 2018, 6, Article number: 21. 

2. E. De Vita, P. Schüler, S. Lovell, J. Lohbeck, S. Kullmann, E. Rabinovich, A. Sananes, B. Heßling, V. Hamon, N. Papo, J. Hess, E. W. Tate, N. Gunkel, A. K. Miller, Depsipeptides featuring a neutral P1 are potent inhibitors of kallikrein-related peptidase 6 with on-target cellular activity, J. Med. Chem., 2018, 61, 8859–8874. Featured on Supplementary CoverArt. 

1. A. Sananes, I. Cohen, A. Shahar, A. Hockla, E. De Vita, A. K. Miller, E. S. Radisky, N. Papo, A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering, J. Biol. Chem., 2018, 33, 12663–12680. 

Patents

2. E. De Vita, D. Brustur, E. W. Tate, A. D. Thomas, T. Burden, M. Tersa, E. Cota, S. Vadodaria, Rab27 Inhibitors, GB Patent Application n° 2416727.2, filed November 13, 2024.

1. A. K. Miller, P. Schüler, E. De Vita, N. Gunkel, Chemical substances which inhibit the enzymatic activity of human kallikrein related peptidase 6 (KLK6), 2017, WO2018065607. 

Honours&Awards